MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
BioNano Genomics Interest Expense 2011-2026 | BNGO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.9 M | -10.1 M | -20.5 M | 298 K | 927 K | 2.52 M | 2.29 M | 1.38 M | 591 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.9 M | -20.5 M | -1.86 M |
Quarterly Interest Expense BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -219 K | 676 K | 5.08 M | - | -697 K | 363 K | -1.36 M | - | -45 K | -330 K | 76 K | - | 73 K | 74 K | 77 K | - | 2 K | 210 K | 603 K | - | 589 K | 561 K | 761 K | - | 578 K | 645 K | 273 K | - | 404 K | 408 K | 302 K | - | 145 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.08 M | -1.36 M | 370 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 120.47 | 0.08 % | $ 36.6 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 20.8 | 4.55 % | $ 224 M |  China |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.73 | 0.57 % | $ 945 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.43 | 3.93 % | $ 1.9 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Precipio
PRPO
|
839 K | $ 29.42 | 3.23 % | $ 47.2 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.69 | 1.29 % | $ 686 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 182.7 | 1.89 % | $ 9.06 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 518.13 | -0.36 % | $ 14.9 B | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.2 | - | $ 9.73 M | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 198.36 | -0.09 % | $ 141 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 132.02 | 1.3 % | $ 21 B | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.66 | 3.77 % | $ 1.11 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 211.11 | -1.64 % | $ 20.8 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 16.3 | 1.75 % | $ 493 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.99 | -0.33 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 85.65 | -0.87 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Myriad Genetics
MYGN
|
800 K | $ 5.32 | 8.35 % | $ 493 M | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.88 | - | $ 93.5 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.09 | -0.64 % | $ 4.8 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.85 | 1.48 % | $ 286 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 114.16 | 0.97 % | $ 9.42 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 267.98 | -0.32 % | $ 22.3 B | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.61 | -0.03 % | $ 2.67 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 123.19 | 1.94 % | $ 5.76 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.46 | -1.61 % | $ 2.05 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 83.13 | 0.47 % | $ 5.61 B | USA |
 |
Neuronetics
STIM
|
716 K | $ 1.44 | 0.35 % | $ 95 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 192.42 | -0.84 % | $ 21.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 5.15 | 3.83 % | $ 4.05 M | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 528.86 | 0.3 % | $ 199 B | USA |